Literature DB >> 27825849

Nuclear receptor retinoid-related orphan receptor α deficiency exacerbates high-fat diet-induced cardiac dysfunction despite improving metabolic abnormality.

Yi-Chao Zhao1, Long-Wei Xu1, Song Ding1, Qing-Qi Ji1, Nan Lin1, Qing He1, Ling-Chen Gao1, Yuan-Yuan Su1, Jun Pu2, Ben He3.   

Abstract

Retinoid-related orphan receptor α (RORα), a member of the metabolic nuclear receptor superfamily, plays a vital regulatory role in circadian rhythm and metabolism. Here, we investigated the role of RORα in high-fat diet (HFD)-induced cardiac impairments and the underlying mechanisms involved. RORα-deficient stagger mice (sg/sg) and wild type (WT) littermates were fed with either standard diet or HFD. At 20weeks after HFD treatment, RORα deficiency resulted in significantly decreased body weight gain, improved dyslipidemia and ameliorated insulin resistance (evaluated by blood biochemical and glucose/insulin tolerance tests) compared with WT control. However, compared with HFD-treated WT mice, HFD-treated sg/sg mice exhibited significantly augmented myocardial hypertrophy, cardiac fibrosis (wheat germ agglutinin, masson trichrome and sirius red staining) and cardiac dysfunction (echocardiography and hemodynamics). Mechanistically, RORα deficiency impaired mitochondrial biogenesis and function. Additionally, RORα deficiency resulted in inhibition of the AMPK-PGC1α signaling pathway. In contrast, cardiomyocyte-specific RORα overexpression ameliorated myocardial hypertrophy, fibrosis and dysfunction by restoring AMPK-PGC1α signaling, and subsequently normalizing mitochondrial biogenesis. These findings demonstrated for the first time that nuclear receptor RORα deficiency aggravated HFD-induced myocardial dysfunction at least in part by impairing mitochondrial biogenesis in association with disrupting AMPK-PGC1α signaling. This article is part of a Special Issue entitled: Genetic and epigenetic control of heart failure - edited by Jun Ren and Megan Yingmei Zhang.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Mitochondrial biogenesis; Myocardial hypertrophy; PGC1α; RORα

Mesh:

Substances:

Year:  2016        PMID: 27825849     DOI: 10.1016/j.bbadis.2016.10.029

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  6 in total

1.  The nuclear receptor RORα protects against angiotensin II-induced cardiac hypertrophy and heart failure.

Authors:  Ju Youn Beak; Hong Soon Kang; Wei Huang; Page H Myers; Dawn E Bowles; Anton M Jetten; Brian C Jensen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-11-02       Impact factor: 4.733

2.  RORα nuclear receptors in protection against angiotensin II-induced cardiac hypertrophy.

Authors:  Anna Zoccarato; Ajay M Shah
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-12-07       Impact factor: 4.733

3.  FNDC5 attenuates obesity-induced cardiac hypertrophy by inactivating JAK2/STAT3-associated inflammation and oxidative stress.

Authors:  Zhi Geng; Wen-Yong Fan; Bing Zhou; Chao Ye; Ying Tong; Ye-Bo Zhou; Xiao-Qing Xiong
Journal:  J Transl Med       Date:  2019-04-02       Impact factor: 5.531

4.  MOF upregulates the estrogen receptor α signaling pathway by its acetylase activity in hepatocellular carcinoma.

Authors:  Shan Wei; Wei Liu; Ning Sun; Yi Wu; Huijuan Song; Chunyu Wang; Shengli Wang; Renlong Zou; Lin Lin; Kai Zeng; Baosheng Zhou; Manlin Wang; Ruina Luan; Fan Yang; Yue Zhao
Journal:  Cancer Sci       Date:  2021-03-30       Impact factor: 6.716

Review 5.  Nuclear Receptor RORα/γ: Exciting Modulators in Metabolic Syndrome and Related Disorders.

Authors:  Haotian Gu; Ping Hu; Yahui Zhao; Yaya Liu; Yi-Ting Wang; Abdelkareem A Ahmed; Hao-Yu Liu; Demin Cai
Journal:  Front Nutr       Date:  2022-06-21

6.  lncRNA FGD5 antisense RNA 1 upregulates RORA to suppress hypoxic injury of human cardiomyocyte cells by inhibiting oxidative stress and apoptosis via miR‑195.

Authors:  Xinyong Cai; Ping Zhang; Shu Wang; Lang Hong; Songping Yu; Bin Li; Hong Zeng; Xu Yang; Liang Shao
Journal:  Mol Med Rep       Date:  2020-10-02       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.